(Q37154788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

FTY720 (fingolimod) for relapsing multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Xavier Montalban

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Alejandro Horga

series ordinal

1

1 reference

18 August 2017

Xavier Montalban

series ordinal

2

1 reference

18 August 2017

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

699-714

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

The epidemiology of multiple sclerosis in Europe.

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Current perspectives on FTY720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720 (fingolimod) in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine-1-phosphate in cell growth and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Signaling and biological actions of sphingosine 1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Essential role for sphingosine kinases in neural and vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Lysophospholipids in development: Miles apart and edging in.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Enzymes of sphingolipid metabolism: from modular to integrative signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Generation and metabolism of bioactive sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Structural and functional characteristics of S1P receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Egress: a receptor-regulated step in lymphocyte trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Pulmonary and vascular pharmacology of sphingosine 1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Endothelial cell barrier regulation by sphingosine 1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Tipping the gatekeeper: S1P regulation of endothelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine-1-phosphate signaling in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Constitutive expression of the S1P1 receptor in adult tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Why does remyelination fail in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Enhancing central nervous system remyelination in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Reactive astrocytes in neural repair and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Qualitative differences between naïve and memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Preferential localization of effector memory cells in nonlymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Synthesis of para-Alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Overview of FTY720 clinical pharmacokinetics and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720 pharmacokinetics in mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Clinical importance of the cytochromes P450

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.5.699

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.208

Identifiers

DOI

10.1586/14737175.8.5.699

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18457527%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference